CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug combo aims to halt advanced prostate cancer in select patients
Disease control OngoingThis study is testing a combination of two drugs, niraparib/abiraterone and prednisone, in men with advanced prostate cancer that has spread and has stopped responding to standard hormone-blocking treatments. The treatment is specifically for patients whose cancer has a particula…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo tested for aggressive bladder and prostate cancers
Disease control OngoingThis early-stage trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for treating advanced small cell or neuroendocrine cancers of the bladder, urethra, or prostate. The study will enroll about 15 participants with cancer tha…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Two-Pronged attack on advanced prostate cancer
Disease control OngoingThis study is testing whether combining two drugs, olaparib and cediranib, is more effective than using olaparib alone for men with advanced prostate cancer that has stopped responding to standard hormone therapy and has spread. The trial aims to see if the drug combo can better …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug combo tested for Tough-to-Treat advanced cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug trial targets Tough-to-Treat prostate cancer with specific gene flaw
Disease control OngoingThis study is testing an experimental drug called M1774 for men with advanced prostate cancer that has a specific genetic change (SPOP mutation) and has stopped responding to standard treatments. The goal is to see if M1774 can shrink or stop the growth of the cancer. About 20 pa…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New attack on tough prostate cancer: Anti-Inflammatory drug joins the fight
Disease control OngoingThis study is testing whether adding an anti-inflammatory drug (golimumab) to a standard prostate cancer hormone blocker (apalutamide) can better control a very advanced form of the disease. It's for men whose cancer has spread and stopped responding to standard hormone treatment…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New Two-Drug attack on tough, spreading cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, DS3201 and ipilimumab, for people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and understand the side effects. Researchers hope the drug combo will …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New Two-Pronged attack on advanced prostate cancer
Disease control OngoingThis study is testing a combination of two drugs, olaparib and radium-223, for men with advanced prostate cancer that has spread to the bones and is no longer responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can slow the cance…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Double attack on prostate cancer: testing a drug combo for tough cases
Disease control OngoingThis study is for men with advanced prostate cancer that has stopped responding to standard hormone therapy and has spread to the bones. It aims to see if adding a targeted radiation drug (Radium223) to a standard cancer-fighting pill (enzalutamide) works better than the pill alo…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug combo aims to tame deadly prostate cancer
Disease control OngoingThis study is testing a multi-step treatment to control a fast-spreading and hard-to-treat form of prostate cancer. It will involve about 120 men whose cancer has spread and is resistant to standard hormone therapy. The goal is to see if combining chemotherapy, a drug that helps …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New immune therapy cocktail tested in fight against advanced cancers
Disease control OngoingThis study is testing the safety and effectiveness of avelumab, an immunotherapy drug, when given in combination with other immune-boosting drugs and sometimes radiation. It is for patients with advanced solid tumors that have spread and who have run out of standard treatment opt…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
New combo attack on tough prostate cancer
Disease control OngoingThis study is for men whose prostate cancer has spread and stopped responding to standard hormone therapy and an initial round of chemotherapy. It tests if adding a second chemotherapy drug (cabazitaxel) to a standard hormone-blocking drug (abiraterone) is more effective at contr…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New hope for Tough-to-Treat prostate cancer
Disease control OngoingThis study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy (carboplatin) works better than a different standard combination (docetaxel + carboplatin) for men with advanced prostate cancer that has spread and is no longer responding to …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New drug duo aims to outsmart advanced prostate cancer
Disease control OngoingThis study is testing if adding a drug called rucaparib to standard treatment (enzalutamide) works better for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the combination helps patients live longer or keeps their cancer fro…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New strategy aims to outsmart resistant prostate cancer
Disease control OngoingThis study is testing different combinations of approved drugs to find better ways to control advanced prostate cancer that has spread and stopped responding to standard hormone therapy. It involves 196 men and uses a personalized approach: after an initial 8-week treatment, pati…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Smart scans aim to target deadly prostate cancer spread
Disease control OngoingThis study is testing whether a special type of imaging scan (PSMA PET) can help doctors better select patients for a targeted radiation treatment called Ra-223. The treatment is for men whose prostate cancer has become resistant to hormone therapy and has spread to their bones. …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC
-
New hope for tough prostate cancer: adding immunotherapy when standard drug fails
Disease control OngoingThis study is testing if adding the immunotherapy drug pembrolizumab can help control advanced prostate cancer that has started growing again despite treatment with the standard drug enzalutamide. It involves about 58 men whose cancer has spread and is no longer responding to hor…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC
-
New drug duo tested in battle against spreading prostate cancer
Disease control OngoingThis study is testing the safety and effectiveness of combining two drugs, enzalutamide and cabazitaxel, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The goal is to see if using these drugs together can better c…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Mar 04, 2026 15:29 UTC